非酒精性脂肪性肝炎

• 拓臻生物(Nasdaq:TERN)登陆美股 2021-02-01
• 拓臻生物完成8700万美元C轮融资，推进NASH新药管线研发 2021-01-05
• Metacrine Announces Pricing of Initial Public Offering 2020-09-16
• Glympse Bio Secures $46.7 Million to Advance NASH Biosensor Program 2020-07-16
• Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants 2020-07-14
• 89bio Announces Pricing of Upsized Public Offering of Common Stock 2020-07-08
• 89bio Announces Proposed Public Offering of Common Stock 2020-07-06
• DiscernDx Acquires Luminist Labs to Expand Precision Medicine Solutions for Chronic Diseases 2020-04-29
• Lipidio Pharmaceuticals Launches with First Close of Series A Financing 2020-03-04
• Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing 2019-10-10

登录医药魔方官网 查看更多资讯